Health AI Central
Share:
Peer-Reviewed Publication
EMBO Mol Med2026;18(2):433-461.February 1, 2026Journal Article

Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.

Katarzyna Radke1, Kristina Aaltonen1, Erick A Muciño-Olmos1, Javanshir Esfandyari1, Aleksandra Adamska1, Joachim T Siaw1, Dora Adamic1, Chiara Lago1, Adriana Mañas1,2,3, Alexandra Seger1, Karin Hansson1,4, Oksana Rogova5, Sophie Lehn1, Daniel J Mason6, Daniel J O'Donovan6, Ian Roberts6, Antonia Lock6,7, Jane Brennan6, Kristian Pietras1, Emma J Davies6, Peter Spégel5, Oscar C Bedoya-Reina8,9, David Brown6, Neil T Thompson6, Cesare Spadoni10, Daniel Bexell11
1Translational Cancer Research, Lund University, Lund, Sweden.
2Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy, IdiPAZ Research Center, University Hospital La Paz, Madrid, Spain.
3Pediatric Onco-hematology Clinical Unit IdiPAZ-CNIO, National Cancer Research Center (CNIO), Madrid, Spain.
4Cancer Stem Cell Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
5Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden.
6Healx Ltd., Charter House, 66-68 Hills Road, Cambridge, CB2 1LA, UK.
7EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK.
8School of Medical Sciences, Örebro University, Örebro, Sweden.
9Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
10aPODD Foundation, Virginia Cottage, Bridgnorth Road, Stourton, Stourbridge, West Midlands, DY7 5BQ, UK.
11Translational Cancer Research, Lund University, Lund, Sweden. daniel.bexell@med.lu.se.
PubMed PMC DOI PDF

Abstract

Relapse and treatment resistance are common in children with high-risk neuroblastoma, and novel therapies are needed. Conventional drug discovery is slow, expensive, often fails in practice, and consequently falls short in addressing pediatric and rare conditions. In such instances, drug repurposing is a promising strategy. Here, we used two independent in silico prediction tools including machine…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.